Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.31 |
| ▸ | PDE2A | O00408 | 2/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12823877 | 0.88 | SERPINE1 (0.38) | KMT2AIDO1TP53GPR119SERPINE1 | |
| SCHEMBL13586418 | 0.87 | PDE2A (0.30) | PDE2A | |
| SCHEMBL13586510 | 0.86 | KCNQ3 (0.39) | KMT2AIDO1 | |
| SCHEMBL12823447 | 0.86 | PDE2A (0.32) | PDE2A | |
| SCHEMBL12823660 | 0.86 | ALOX5AP (0.32) | — | |
| SCHEMBL12823921 | 0.85 | CYP2C9 (0.38) | KMT2ATP53GPR119SERPINE1ALDH1A1 | |
| SCHEMBL13586320 | 0.85 | PDE4A (0.32) | KMT2A | |
| SCHEMBL12823923 | 0.84 | PDE2A (0.30) | PDE2A | |
| SCHEMBL12823918 | 0.83 | KMT2A (0.38) | KMT2ATP53SERPINE1PDE2AALDH1A1 | |
| SCHEMBL12823184 | 0.82 | ALOX5AP (0.33) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | KMT2A 1271/4885IDO1 1869/4885TP53 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.